


AMENDMENTS TO THE CLAIMS

1-20 (canceled).

21. (Currently Amended) ~~A compound selected from the group consisting of:~~

~~a compound of formula I~~



~~wherein R_1 and R_2 are independently hydrogen, a straight chained C_{1-6} alkyl group optionally substituted with a phenyl group, or a branched C_{1-6} alkyl group optionally substituted with a phenyl group, or~~

~~R_1 and R_2 together with the nitrogen atom attached thereto form a 5-7 membered saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatoms; wherein the heterocyclic ring is optionally substituted with one or more hydroxy, oxo or benzyl groups;~~

~~A is a phenyl group optionally substituted with one or more C_{1-4} alkyl, C_{1-4} haloalkyl, nitro group, or halogen, or is a 5-6 membered heteroaromatic ring containing at least one heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, wherein the nitrogen heteroatom is optionally an N-oxide structure;~~

~~n is 0, 1, or 2;~~

~~z is 0 or 1;~~

~~X is halogen or NR_4R_5 , wherein R_4 and R_5 are independently hydrogen, a straight chained C_{1-6} alkyl group or a branched C_{1-6} alkyl group;~~

~~Y is a hydrogen, hydroxy group, halogen, or C_{1-22} acyloxy group, wherein if R_4 and R_5 are both hydrogen, then Y is other than a hydroxy group, with the proviso that~~

~~a) if Y is hydrogen and/or X is an NR_4R_5 or if X is NR_4R_5 group,~~


~~R_1 and R_2 together with the nitrogen atom attached thereto form a 5-7 membered, saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatom, wherein the heterocyclic ring is substituted with one or more hydroxy, oxy, or benzyl groups, and/or~~

~~A is a nitrogen containing heteroaromatic ring, wherein said ring has an N-oxide structure on the nitrogen heteroatom, or~~

~~b) if X is halogen and Y is hydroxy or acyloxy,~~

~~R_1 and R_2 together with the nitrogen atom attached thereto form a 5-7 membered, saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatom, wherein said heterocyclic ring is substituted with one or more hydroxy, oxo or benzyl groups, or a stereoisomer or salt thereof;~~

~~a compound of formula II~~



~~wherein R_1 and R_2 are independently hydrogen, a straight chained C_{1-6} alkyl group optionally substituted with a phenyl group, a branched C_{1-6} alkyl group optionally substituted with a phenyl group, or~~

~~R_1 and R_2 together with the nitrogen atom attached thereto form a 5-7 membered saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatoms, wherein said heterocyclic ring is optionally substituted with one or more hydroxy, oxo or benzyl groups;~~

~~A is a phenyl group optionally substituted with one or more C_{1-4} alkyl, C_{1-4} haloalkyl, nitro, or halogen, or is a 5-6 membered heteroaromatic ring containing at least one heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, wherein the nitrogen heteroatom is optionally an N-oxide structure;~~

~~n is 0, 1, or 2;~~

~~z is 0 or 1;~~

~~X is oxygen;~~

~~R₃ is selected from the group consisting of hydrogen, straight chained C₁₋₆ alkyl group, and branched chained C₁₋₆ alkyl group;~~

~~Y is selected from the group consisting of hydrogen, hydroxy, halogen, and C₁₋₂₂ acyloxy group;~~


~~with the proviso that if Y is other than halogen,~~

~~R₁ and R₂ together with the nitrogen atom attached thereto form a 5-7 membered, saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatom, wherein said heterocyclic ring is substituted with one or more hydroxy, oxo or benzyl groups and/or~~

~~A is a nitrogen containing heteroaromatic ring, which has N oxide structure on the nitrogen heteroatom;~~

~~or a stereoisomer or salt thereof; and~~

~~[[a]]A compound of formula III~~



wherein R₁ and R₂ are independently hydrogen, straight chained C₁₋₆ alkyl group optionally substituted with a phenyl group, branched C₁₋₆ alkyl group optionally substituted with a phenyl group, or

R₁ and R₂ together with the nitrogen atom attached thereto form a 5-7 membered saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatom, wherein said heterocyclic ring is optionally substituted with one or more hydroxy, oxo or benzyl groups;

A is a phenyl group optionally substituted with one or more C₁₋₄ alkyl, C₁₋₄ haloalkyl, nitro, or halogen, or is a 5-6 membered heteroaromatic ring containing at least one heteroatom is

selected from the group consisting of nitrogen, oxygen and sulfur, wherein the nitrogen heteroatom is optionally an N-oxide structure;

n is 0, 1, or 2;

z is 0 or 1;

with the proviso that

if R₁ and R₂ independently represent a hydrogen atom, a straight chained C₁₋₆ alkyl group optionally substituted with a phenyl group, a branched C₁₋₆ alkyl group optionally substituted with a phenyl group, or together with the nitrogen atom attached thereto form a 5-7 membered saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatom, then A is a heteroaromatic ring containing oxygen or sulfur heteroatom or an N-containing heteroaromatic ring having an N-oxide structure on the nitrogen heteroatom and

if A is a phenyl group optionally substituted with one or more C₁₋₄ alkyl, C₁₋₄ haloalkyl or nitro groups or halogen, or is a 5-6 membered N-containing heteroaromatic ring, then R₁ and R₂ together with the nitrogen atom attached thereto form a 5-7 membered saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatom, wherein said heterocyclic ring is substituted with one or more hydroxy, oxo, or benzyl groups;

or a stereoisomer or salt thereof.

22-26. (Canceled)

27. (Previously Presented) The compound according to claim 21, wherein the compound is 5,6-dihydro-5-[(1-piperidiny)methyl]-3-(1-oxido-3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

28. (Previously Presented) The compound according to claim 21, wherein the compound is 5,6-dihydro-5-[(4-benzyl-1-piperidiny)methyl]-3-(3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

29. (Currently Amended) The compound according to claim 21, wherein the compound is 5,6-dihydro-5-[(4-benzyl-2-oxo-1-piperidiny)methyl]-3-(3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

30. (Currently Amended) The compound according to claim ~~21~~27, wherein the compound is (+)-5,6-dihydro-5-[(1-piperidinyl)methyl]-3-(1-oxido-3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

31. (Currently Amended) The compound according to claim 21, wherein the compound is 5,6-dihydro-5-[(1-oxido-1-piperidinyl)methyl]-3-(1-oxido-3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

32. (Previously Presented) The compound according to claim 21, wherein the compound is 5,6-dihydro-5-[(4-hydroxy-1-piperidinyl)methyl]-3-(3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

33-34. (Canceled)

35. (Currently Amended) A pharmaceutical composition comprising a compound of formulae ~~I, H, or~~ III as defined in claim ~~[[22]]~~21 and a pharmaceutically acceptable carrier.

36. (Currently Amended) A method for the treatment ~~or prevention~~ of vascular disease ~~or diseases related to vascular disorders~~ comprising administering an effective amount of a compound to a patient, wherein the compound is a compound of formulae ~~I, H, or~~ III as defined in claim ~~[[22]]~~21.

37. (New) A method for the relaxation of blood vessels comprising administering an effective amount of a compound to a patient, wherein the compound is a compound of formula III as defined in claim 21.